Novel insights into the biology and treatment of chronic myeloproliferative neoplasms

Tariq I. Mughal, Tiziano Barbui, Omar Abdel-Wahab, Robert Kralovics, Catriona Jamieson, Hans Michael Kvasnicka, Ann Mullaly, Raajit Rampal, Ruben Mesa, Jean Jacques Kiladjian, Michael Deininger, Josef Prchal, Rüdiger Hehlmann, Giuseppe Saglio, Richard A. Van Etten

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoiesis characterized by a high frequency of genetic alterations, and include chronic myeloid leukemia (CML) and the BCR-ABL1-negative MPNs. Herein we summarize recent advances and controversies in our understanding of the biology and therapy of these disorders, as discussed at the 8th post-American Society of Hematology CML-MPN workshop. The principal areas addressed include the breakthrough discovery of CALR mutations in patients with JAK2/MPL wild type MPN, candidate therapies based on novel genetic findings in leukemic transformation and new therapeutic targets in MPNs, and an appraisal of bone marrow histopathology in MPNs with a focus on the potential new clinical entity of "masked" polycythemia vera. An update on clinical trials of Janus kinase (JAK) inhibitors is presented as well as current understanding regarding the definitions and mechanisms of resistance to JAK inhibitors, and updated information on the safety and efficacy of discontinuation of tyrosine kinase inhibitors in patients with CML.

Original languageEnglish (US)
Pages (from-to)1938-1948
Number of pages11
JournalLeukemia and Lymphoma
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Janus Kinases
Neoplasms
Bone Marrow Neoplasms
Therapeutics
Polycythemia Vera
Hematopoiesis
Protein-Tyrosine Kinases
Clinical Trials
Safety
Education
Mutation

Keywords

  • Molecular genetics
  • Myeloid leukemias and dysplasias
  • Myeloproliferative disorders
  • Prognostication
  • Signaling therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mughal, T. I., Barbui, T., Abdel-Wahab, O., Kralovics, R., Jamieson, C., Kvasnicka, H. M., ... Van Etten, R. A. (2015). Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 56(7), 1938-1948. https://doi.org/10.3109/10428194.2014.974594

Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. / Mughal, Tariq I.; Barbui, Tiziano; Abdel-Wahab, Omar; Kralovics, Robert; Jamieson, Catriona; Kvasnicka, Hans Michael; Mullaly, Ann; Rampal, Raajit; Mesa, Ruben; Kiladjian, Jean Jacques; Deininger, Michael; Prchal, Josef; Hehlmann, Rüdiger; Saglio, Giuseppe; Van Etten, Richard A.

In: Leukemia and Lymphoma, Vol. 56, No. 7, 01.07.2015, p. 1938-1948.

Research output: Contribution to journalArticle

Mughal, TI, Barbui, T, Abdel-Wahab, O, Kralovics, R, Jamieson, C, Kvasnicka, HM, Mullaly, A, Rampal, R, Mesa, R, Kiladjian, JJ, Deininger, M, Prchal, J, Hehlmann, R, Saglio, G & Van Etten, RA 2015, 'Novel insights into the biology and treatment of chronic myeloproliferative neoplasms', Leukemia and Lymphoma, vol. 56, no. 7, pp. 1938-1948. https://doi.org/10.3109/10428194.2014.974594
Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM et al. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma. 2015 Jul 1;56(7):1938-1948. https://doi.org/10.3109/10428194.2014.974594
Mughal, Tariq I. ; Barbui, Tiziano ; Abdel-Wahab, Omar ; Kralovics, Robert ; Jamieson, Catriona ; Kvasnicka, Hans Michael ; Mullaly, Ann ; Rampal, Raajit ; Mesa, Ruben ; Kiladjian, Jean Jacques ; Deininger, Michael ; Prchal, Josef ; Hehlmann, Rüdiger ; Saglio, Giuseppe ; Van Etten, Richard A. / Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 7. pp. 1938-1948.
@article{9fa82a472cf64c359e4c584057719131,
title = "Novel insights into the biology and treatment of chronic myeloproliferative neoplasms",
abstract = "Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoiesis characterized by a high frequency of genetic alterations, and include chronic myeloid leukemia (CML) and the BCR-ABL1-negative MPNs. Herein we summarize recent advances and controversies in our understanding of the biology and therapy of these disorders, as discussed at the 8th post-American Society of Hematology CML-MPN workshop. The principal areas addressed include the breakthrough discovery of CALR mutations in patients with JAK2/MPL wild type MPN, candidate therapies based on novel genetic findings in leukemic transformation and new therapeutic targets in MPNs, and an appraisal of bone marrow histopathology in MPNs with a focus on the potential new clinical entity of {"}masked{"} polycythemia vera. An update on clinical trials of Janus kinase (JAK) inhibitors is presented as well as current understanding regarding the definitions and mechanisms of resistance to JAK inhibitors, and updated information on the safety and efficacy of discontinuation of tyrosine kinase inhibitors in patients with CML.",
keywords = "Molecular genetics, Myeloid leukemias and dysplasias, Myeloproliferative disorders, Prognostication, Signaling therapies",
author = "Mughal, {Tariq I.} and Tiziano Barbui and Omar Abdel-Wahab and Robert Kralovics and Catriona Jamieson and Kvasnicka, {Hans Michael} and Ann Mullaly and Raajit Rampal and Ruben Mesa and Kiladjian, {Jean Jacques} and Michael Deininger and Josef Prchal and R{\"u}diger Hehlmann and Giuseppe Saglio and {Van Etten}, {Richard A.}",
year = "2015",
month = "7",
day = "1",
doi = "10.3109/10428194.2014.974594",
language = "English (US)",
volume = "56",
pages = "1938--1948",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Novel insights into the biology and treatment of chronic myeloproliferative neoplasms

AU - Mughal, Tariq I.

AU - Barbui, Tiziano

AU - Abdel-Wahab, Omar

AU - Kralovics, Robert

AU - Jamieson, Catriona

AU - Kvasnicka, Hans Michael

AU - Mullaly, Ann

AU - Rampal, Raajit

AU - Mesa, Ruben

AU - Kiladjian, Jean Jacques

AU - Deininger, Michael

AU - Prchal, Josef

AU - Hehlmann, Rüdiger

AU - Saglio, Giuseppe

AU - Van Etten, Richard A.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoiesis characterized by a high frequency of genetic alterations, and include chronic myeloid leukemia (CML) and the BCR-ABL1-negative MPNs. Herein we summarize recent advances and controversies in our understanding of the biology and therapy of these disorders, as discussed at the 8th post-American Society of Hematology CML-MPN workshop. The principal areas addressed include the breakthrough discovery of CALR mutations in patients with JAK2/MPL wild type MPN, candidate therapies based on novel genetic findings in leukemic transformation and new therapeutic targets in MPNs, and an appraisal of bone marrow histopathology in MPNs with a focus on the potential new clinical entity of "masked" polycythemia vera. An update on clinical trials of Janus kinase (JAK) inhibitors is presented as well as current understanding regarding the definitions and mechanisms of resistance to JAK inhibitors, and updated information on the safety and efficacy of discontinuation of tyrosine kinase inhibitors in patients with CML.

AB - Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoiesis characterized by a high frequency of genetic alterations, and include chronic myeloid leukemia (CML) and the BCR-ABL1-negative MPNs. Herein we summarize recent advances and controversies in our understanding of the biology and therapy of these disorders, as discussed at the 8th post-American Society of Hematology CML-MPN workshop. The principal areas addressed include the breakthrough discovery of CALR mutations in patients with JAK2/MPL wild type MPN, candidate therapies based on novel genetic findings in leukemic transformation and new therapeutic targets in MPNs, and an appraisal of bone marrow histopathology in MPNs with a focus on the potential new clinical entity of "masked" polycythemia vera. An update on clinical trials of Janus kinase (JAK) inhibitors is presented as well as current understanding regarding the definitions and mechanisms of resistance to JAK inhibitors, and updated information on the safety and efficacy of discontinuation of tyrosine kinase inhibitors in patients with CML.

KW - Molecular genetics

KW - Myeloid leukemias and dysplasias

KW - Myeloproliferative disorders

KW - Prognostication

KW - Signaling therapies

UR - http://www.scopus.com/inward/record.url?scp=84938149109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938149109&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.974594

DO - 10.3109/10428194.2014.974594

M3 - Article

VL - 56

SP - 1938

EP - 1948

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -